ES2333319T3 - Receptores de la neurotoxina botulinica b y su uso. - Google Patents
Receptores de la neurotoxina botulinica b y su uso. Download PDFInfo
- Publication number
- ES2333319T3 ES2333319T3 ES03816739T ES03816739T ES2333319T3 ES 2333319 T3 ES2333319 T3 ES 2333319T3 ES 03816739 T ES03816739 T ES 03816739T ES 03816739 T ES03816739 T ES 03816739T ES 2333319 T3 ES2333319 T3 ES 2333319T3
- Authority
- ES
- Spain
- Prior art keywords
- syt
- bont
- baselineskip
- binding
- gangliosides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000027455 binding Effects 0.000 claims abstract description 179
- 150000002270 gangliosides Chemical class 0.000 claims abstract description 135
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 87
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 78
- 229920001184 polypeptide Polymers 0.000 claims abstract description 75
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 44
- 238000000034 method Methods 0.000 claims abstract description 33
- 231100000419 toxicity Toxicity 0.000 claims abstract description 23
- 230000001988 toxicity Effects 0.000 claims abstract description 23
- 241000193155 Clostridium botulinum Species 0.000 claims abstract description 6
- 108030001720 Bontoxilysin Proteins 0.000 claims description 303
- 150000001413 amino acids Chemical class 0.000 claims description 72
- 241000282414 Homo sapiens Species 0.000 claims description 36
- 230000009467 reduction Effects 0.000 claims description 7
- 108010001857 Cell Surface Receptors Proteins 0.000 claims description 4
- 102000006240 membrane receptors Human genes 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 229940079593 drug Drugs 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 abstract description 27
- 108020004707 nucleic acids Proteins 0.000 abstract description 27
- 150000007523 nucleic acids Chemical class 0.000 abstract description 27
- 230000001413 cellular effect Effects 0.000 abstract description 3
- 108010074523 rimabotulinumtoxinB Proteins 0.000 abstract description 2
- 101710117524 Botulinum neurotoxin type B Proteins 0.000 abstract 10
- 108010055170 Synaptotagmin I Proteins 0.000 abstract 1
- 108010055445 Synaptotagmin II Proteins 0.000 abstract 1
- 102100036417 Synaptotagmin-1 Human genes 0.000 abstract 1
- 102100036151 Synaptotagmin-2 Human genes 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 120
- 239000012634 fragment Substances 0.000 description 70
- 239000003053 toxin Substances 0.000 description 54
- 231100000765 toxin Toxicity 0.000 description 54
- 108700012359 toxins Proteins 0.000 description 54
- 241000700159 Rattus Species 0.000 description 34
- 241000699666 Mus <mouse, genus> Species 0.000 description 30
- 108090000623 proteins and genes Proteins 0.000 description 30
- 102000004169 proteins and genes Human genes 0.000 description 27
- 235000018102 proteins Nutrition 0.000 description 26
- 238000002474 experimental method Methods 0.000 description 23
- 238000012360 testing method Methods 0.000 description 22
- 230000000694 effects Effects 0.000 description 21
- 230000003993 interaction Effects 0.000 description 19
- 102000005962 receptors Human genes 0.000 description 16
- 108020003175 receptors Proteins 0.000 description 16
- 230000006870 function Effects 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 12
- 230000024033 toxin binding Effects 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 230000028023 exocytosis Effects 0.000 description 11
- 108020001507 fusion proteins Proteins 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 239000013598 vector Substances 0.000 description 11
- 239000011324 bead Substances 0.000 description 10
- 238000003119 immunoblot Methods 0.000 description 10
- 210000005036 nerve Anatomy 0.000 description 10
- 108091033319 polynucleotide Proteins 0.000 description 10
- 102000040430 polynucleotide Human genes 0.000 description 10
- 239000002157 polynucleotide Substances 0.000 description 10
- 241000894007 species Species 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 230000001419 dependent effect Effects 0.000 description 9
- 102200024062 rs1235912910 Human genes 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 238000006386 neutralization reaction Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 108010057722 Synaptosomal-Associated Protein 25 Proteins 0.000 description 7
- 102000004183 Synaptosomal-Associated Protein 25 Human genes 0.000 description 7
- 108030001722 Tentoxilysin Proteins 0.000 description 7
- 229920004890 Triton X-100 Polymers 0.000 description 7
- 239000013504 Triton X-100 Substances 0.000 description 7
- 210000000170 cell membrane Anatomy 0.000 description 7
- 241000283707 Capra Species 0.000 description 6
- 241000283973 Oryctolagus cuniculus Species 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- 210000002569 neuron Anatomy 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000000903 blocking effect Effects 0.000 description 5
- 239000000872 buffer Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 230000012202 endocytosis Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 238000010166 immunofluorescence Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000012546 transfer Methods 0.000 description 5
- 239000003656 tris buffered saline Substances 0.000 description 5
- 108091026890 Coding region Proteins 0.000 description 4
- 101150062179 II gene Proteins 0.000 description 4
- 108010058683 Immobilized Proteins Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 4
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 4
- 102000006384 Soluble N-Ethylmaleimide-Sensitive Factor Attachment Proteins Human genes 0.000 description 4
- 108010019040 Soluble N-Ethylmaleimide-Sensitive Factor Attachment Proteins Proteins 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 239000002041 carbon nanotube Substances 0.000 description 4
- 230000000295 complement effect Effects 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 238000000159 protein binding assay Methods 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- 208000003508 Botulism Diseases 0.000 description 3
- 101100395023 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-7 gene Proteins 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 101150052863 THY1 gene Proteins 0.000 description 3
- 239000000074 antisense oligonucleotide Substances 0.000 description 3
- 238000012230 antisense oligonucleotides Methods 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000007541 cellular toxicity Effects 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000001378 electrochemiluminescence detection Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000028161 membrane depolarization Effects 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 239000002581 neurotoxin Substances 0.000 description 3
- 231100000618 neurotoxin Toxicity 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 210000003463 organelle Anatomy 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 239000000816 peptidomimetic Substances 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 241000064494 Diplobatis ommata Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- 101710138657 Neurotoxin Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 241000700161 Rattus rattus Species 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 108091008324 binding proteins Proteins 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 238000000749 co-immunoprecipitation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 229910052737 gold Inorganic materials 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000034217 membrane fusion Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 210000004412 neuroendocrine cell Anatomy 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004850 protein–protein interaction Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 210000003370 receptor cell Anatomy 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 2
- 238000007423 screening assay Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000005062 synaptic transmission Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- QFVHZQCOUORWEI-UHFFFAOYSA-N 4-[(4-anilino-5-sulfonaphthalen-1-yl)diazenyl]-5-hydroxynaphthalene-2,7-disulfonic acid Chemical compound C=12C(O)=CC(S(O)(=O)=O)=CC2=CC(S(O)(=O)=O)=CC=1N=NC(C1=CC=CC(=C11)S(O)(=O)=O)=CC=C1NC1=CC=CC=C1 QFVHZQCOUORWEI-UHFFFAOYSA-N 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 101500000960 Bacillus anthracis Protective antigen PA-63 Proteins 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 1
- 108010005730 R-SNARE Proteins Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 239000012891 Ringer solution Substances 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 102000001435 Synapsin Human genes 0.000 description 1
- 108050009621 Synapsin Proteins 0.000 description 1
- 102000002215 Synaptobrevin Human genes 0.000 description 1
- 102000050389 Syntaxin Human genes 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 102000036859 Zinc-dependent proteases Human genes 0.000 description 1
- 108091006973 Zinc-dependent proteases Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000012984 biological imaging Methods 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- ROJMAHHOFDIQTI-UHFFFAOYSA-L calcium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydron;piperazine Chemical compound [Ca+2].C1CNCCN1.OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ROJMAHHOFDIQTI-UHFFFAOYSA-L 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- PSLWZOIUBRXAQW-UHFFFAOYSA-M dimethyl(dioctadecyl)azanium;bromide Chemical compound [Br-].CCCCCCCCCCCCCCCCCC[N+](C)(C)CCCCCCCCCCCCCCCCCC PSLWZOIUBRXAQW-UHFFFAOYSA-M 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000002073 fluorescence micrograph Methods 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 150000002339 glycosphingolipids Chemical class 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000012744 immunostaining Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 238000006384 oligomerization reaction Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000011049 pearl Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000032537 response to toxin Effects 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 210000004739 secretory vesicle Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 125000005629 sialic acid group Chemical group 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 210000002504 synaptic vesicle Anatomy 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- JGVWCANSWKRBCS-UHFFFAOYSA-N tetramethylrhodamine thiocyanate Chemical compound [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=C(SC#N)C=C1C(O)=O JGVWCANSWKRBCS-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Obesity (AREA)
- Neurosurgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42295102P | 2002-10-31 | 2002-10-31 | |
| US422951P | 2002-10-31 | ||
| US49812803P | 2003-08-27 | 2003-08-27 | |
| US498128P | 2003-08-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2333319T3 true ES2333319T3 (es) | 2010-02-19 |
Family
ID=34197667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES03816739T Expired - Lifetime ES2333319T3 (es) | 2002-10-31 | 2003-10-28 | Receptores de la neurotoxina botulinica b y su uso. |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20040191887A1 (https=) |
| EP (1) | EP1578382B1 (https=) |
| JP (2) | JP2006512090A (https=) |
| AT (1) | ATE442161T1 (https=) |
| AU (1) | AU2003304419A1 (https=) |
| CA (1) | CA2504532C (https=) |
| DE (1) | DE60329225D1 (https=) |
| ES (1) | ES2333319T3 (https=) |
| IL (1) | IL167943A (https=) |
| WO (1) | WO2005016233A2 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2504532C (en) * | 2002-10-31 | 2014-09-16 | Wisconsin Alumni Research Foundation | Botulinum neurotoxin b receptors and use thereof |
| US7341843B2 (en) * | 2003-04-11 | 2008-03-11 | Allergan, Inc. | Botulinum toxin A peptides and methods of predicting and reducing immunoresistance to botulinum toxin therapy |
| WO2006113648A2 (en) * | 2005-04-18 | 2006-10-26 | University Of Massachusetts | Hn-33 compositions and methods |
| DE102005019302A1 (de) * | 2005-04-26 | 2006-11-16 | Toxogen Gmbh | Carrier zum Targeting von Nervenzellen |
| US7985554B2 (en) | 2005-10-14 | 2011-07-26 | Wisconsin Alumni Research Foundation | Botulinum neurotoxin A receptor and the use thereof |
| DE102005051789B4 (de) | 2005-10-28 | 2014-08-07 | Toxogen Gmbh | Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen |
| KR101226604B1 (ko) | 2007-09-14 | 2013-01-28 | 바이오센티넬, 인코포레이티드 | 절단 서열 및 스페이서를 이용한 공명 에너지 전달 분석 |
| US10908146B2 (en) | 2011-06-01 | 2021-02-02 | Biomadison, Inc. | Compositions and methods for improving sensitivity in cell based assays |
| US12422428B2 (en) | 2011-06-01 | 2025-09-23 | Biomadison, Inc. | Compositions and methods for cell-based assays |
| US9303285B2 (en) | 2012-01-04 | 2016-04-05 | Biomadison, Inc. | Methods and compounds for increasing sensitivity of botulinum assays |
| KR101910490B1 (ko) | 2011-06-01 | 2018-10-22 | 바이오메디슨, 인코퍼레이티드 | 비-ｆｒｅｔ 보툴리눔 검정법 |
| US11325954B2 (en) | 2011-06-01 | 2022-05-10 | Biomadison, Inc. | Compositions and methods for stability testing of botulinum toxin |
| LT3030905T (lt) * | 2013-08-09 | 2018-01-25 | Biomadison, Inc. | Padidinto jautrumo botulino toksino tyrimas |
| EP4516316A4 (en) * | 2022-04-25 | 2026-04-22 | Jiksak Bioengineering Inc | TARGETING AGENT |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6994995B1 (en) * | 2001-03-16 | 2006-02-07 | Lexicon Genetics Incorporated | Human synaptotagmin and polynucleotides encoding the same |
| US8022172B2 (en) * | 2001-08-28 | 2011-09-20 | Allergan, Inc. | Luminescence resonance energy transfer (LRET) assays for clostridial toxin activity |
| US7176278B2 (en) * | 2001-08-30 | 2007-02-13 | Biorexis Technology, Inc. | Modified transferrin fusion proteins |
| CA2504532C (en) * | 2002-10-31 | 2014-09-16 | Wisconsin Alumni Research Foundation | Botulinum neurotoxin b receptors and use thereof |
| US8137924B2 (en) * | 2003-12-19 | 2012-03-20 | Wisconsin Alumni Research Foundation | Method and compositions for detecting botulinum neurotoxin |
| ES2351942T3 (es) * | 2005-04-05 | 2011-02-14 | Allergan Inc | Analisis de la actividad de una toxina clostridial. |
| CA2617877A1 (en) * | 2005-08-02 | 2007-04-19 | Planet Biotechnology, Inc. | Improved chimeric toxin receptor proteins and chimeric toxin receptor proteins for treatment and prevention of anthrax |
| US7985554B2 (en) * | 2005-10-14 | 2011-07-26 | Wisconsin Alumni Research Foundation | Botulinum neurotoxin A receptor and the use thereof |
| EP2734635A1 (en) * | 2011-07-19 | 2014-05-28 | ETH Zürich | Means and methods for determining clostridial neurotoxins |
-
2003
- 2003-10-28 CA CA2504532A patent/CA2504532C/en not_active Expired - Fee Related
- 2003-10-28 ES ES03816739T patent/ES2333319T3/es not_active Expired - Lifetime
- 2003-10-28 DE DE60329225T patent/DE60329225D1/de not_active Expired - Lifetime
- 2003-10-28 WO PCT/US2003/034348 patent/WO2005016233A2/en not_active Ceased
- 2003-10-28 AU AU2003304419A patent/AU2003304419A1/en not_active Abandoned
- 2003-10-28 US US10/695,577 patent/US20040191887A1/en not_active Abandoned
- 2003-10-28 EP EP03816739A patent/EP1578382B1/en not_active Expired - Lifetime
- 2003-10-28 JP JP2005507928A patent/JP2006512090A/ja active Pending
- 2003-10-28 AT AT03816739T patent/ATE442161T1/de not_active IP Right Cessation
-
2005
- 2005-04-10 IL IL167943A patent/IL167943A/en unknown
-
2009
- 2009-10-01 JP JP2009229744A patent/JP2010006833A/ja active Pending
-
2011
- 2011-10-26 US US13/281,501 patent/US8617573B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005016233A2 (en) | 2005-02-24 |
| JP2006512090A (ja) | 2006-04-13 |
| ATE442161T1 (de) | 2009-09-15 |
| AU2003304419A8 (en) | 2005-03-07 |
| CA2504532A1 (en) | 2005-02-24 |
| JP2010006833A (ja) | 2010-01-14 |
| AU2003304419A1 (en) | 2005-03-07 |
| US20120082672A1 (en) | 2012-04-05 |
| EP1578382B1 (en) | 2009-09-09 |
| EP1578382A4 (en) | 2007-08-29 |
| IL167943A (en) | 2010-12-30 |
| US8617573B2 (en) | 2013-12-31 |
| DE60329225D1 (de) | 2009-10-22 |
| EP1578382A2 (en) | 2005-09-28 |
| CA2504532C (en) | 2014-09-16 |
| WO2005016233A3 (en) | 2005-08-18 |
| US20040191887A1 (en) | 2004-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8617573B2 (en) | Botulinum neurotoxin B receptors and use thereof | |
| Dong et al. | Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells | |
| Demberg et al. | Activation of adhesion G protein-coupled receptors: agonist specificity of Stachel sequence-derived peptides | |
| US8450277B2 (en) | Methods for reducing botulinum neurotoxin A toxicity | |
| Rummel et al. | The HCC‐domain of botulinum neurotoxins A and B exhibits a singular ganglioside binding site displaying serotype specific carbohydrate interaction | |
| Wilde et al. | The constitutive activity of the adhesion GPCR GPR114/ADGRG5 is mediated by its tethered agonist | |
| Ojima et al. | Non-proteolytic functions of calpain-3 in sarcoplasmic reticulum in skeletal muscles | |
| Liu et al. | Structural basis for botulinum neurotoxin E recognition of synaptic vesicle protein 2 | |
| US8771707B2 (en) | Botulinum neurotoxin E receptors and uses thereof | |
| WO2017024204A1 (en) | Engineered enzyme for enzyme replacement therapy | |
| Yelin et al. | Glycosylation of a vesicular monoamine transporter: a mutation in a conserved proline residue affects the activity, glycosylation, and localization of the transporter | |
| WO2021225781A2 (en) | Aberrant post-translational modifications (ptms) in methyl- and propionic acidemia and a mutant sirtuin (sirt) to metabolize ptms | |
| US12077607B2 (en) | Functional and therapeutic effects of PAR4 cleavage by cathepsin G | |
| Yamada et al. | Role of serine 249 of ezrin in the regulation of sodium-dependent phosphate transporter NaPi-IIa activity in renal proximal tubular cells | |
| Li et al. | Ca sup 2+-dependent and-independent activities of neural and non-neural synaptotagmins | |
| JP4445291B2 (ja) | 新規タンパク質およびそのｄｎａ | |
| US20150268247A1 (en) | Assay for Screening of Anti-Viral Compounds That Inhibit Specific Interaction Interfaces Between Cullin5 and an ElonginB/ElonginC/ CBF-beta/HIV-1 Vif Complex | |
| Rothemund et al. | Lilian M. Demberg1, Jana Winkler1, Caroline Wilde1, Kay-Uwe Simon1, Julia Schön1, Sven | |
| Al Tobi | Consequences of tyrosine phosphorylation of Syntaxin4 and Munc18c on GLUT4 trafficking | |
| Koticha | The cysteine-rich domain of SNAP-25 is necessary for plasma membrane targeting and regulated exocytosis | |
| Parker | Characterisation of C-terminal RyR1 variants linked to neuromuscular disorders: a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Genetics at Massey University, Manawatū, New Zealand | |
| Callan | Early events in the biosynthesis of torsinA | |
| JP2004121246A (ja) | 神経変性疾患の予防・治療剤 | |
| JP2004135666A (ja) | 神経変性疾患の予防・治療剤 |